SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending after a significant post-earnings sell-off, despite beating Q4 estimates, as conservative Q1 guidance and concerns over AI chip sales to China have sparked community debate over whether the sharp decline is an overreaction or market manipulation impacting the broader semiconductor sector.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing a significant sell-off despite reporting strong earnings, fueling intense community debate over its high valuation amid broader tech sector weakness and aggressive profit-taking.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending intensely ahead of its pivotal earnings report, as the community eagerly anticipates details on its AI monetization and cloud growth, while debating if strong results will boost the broader market or lead to a re-evaluation of its high valuation.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending due to significant community discussion surrounding a recently contested short-seller report and its potential involvement, through affiliates, in the Department of War's Drone Dominance Program. Despite recent defense contract wins and an acquisition, volatility is widely attributed to broader tech sector weakness and perceived market manipulation, prompting many to view current levels as a long-term buying opportunity.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is a focal point ahead of its upcoming earnings report, with the community highly anticipating how its AI advancements like Gemini, coupled with Waymo's substantial funding and expansion, will impact its performance and potentially influence the broader tech market amidst ongoing volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing significant volatility and trending due to a broad market sell-off impacting AI and crypto-related stocks, fueling accusations of manipulation ahead of its upcoming earnings report. The community is sharply divided between those seizing the deep dip as a buying opportunity based on strong AI infrastructure fundamentals and high expectations for a potential new hyperscaler deal, and others bracing for further declines if anticipated announcements fall short.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy surged after reporting a strong earnings beat and optimistic guidance, sparking a massive short squeeze and multiple analyst upgrades. This performance on a weak market day has ignited community discussion about a potential turnaround in the solar sector.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending amid sharp volatility, with many investors actively buying the dip, viewing current price levels as an oversold opportunity for a pure-play AI infrastructure leader. Community sentiment remains strong, buoyed by significant contracts with tech giants, NVIDIA partnerships for next-gen compute, and anticipation for its upcoming earnings report.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a significant downturn sweeps across the semiconductor sector, fueled by broader market weakness, a peer's lower guidance, and notable bearish options activity. Community discussion is sharply divided between those seizing the dip as a prime long-term AI memory investment and those anticipating a deeper "bubble burst".

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending amid a $2 billion non-dilutive debt offering to finance its Amazon-leased Black Pearl data center, reinforcing its strategic pivot to AI infrastructure. The community is actively discussing this move and a recent analyst upgrade, while debating if the stock is truly decoupling from volatile Bitcoin prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Artelo Biosciences, Inc. (ARTL) surged 57% on Monday afternoon after the company announced positive preclinical data highlighting the potential of its drug candidate in treating depression and anxiety.The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with leading antidepressant medication, Sertraline (Zoloft).ART12.11 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.artelobio.com/news-events/press-releases/detail/153/artelo-biosciences-announces-positive-preclinical-efficacy">improved</a> sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.However, unlike Sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, the company added.<a href="https://stocktwits.com/symbol/ARTL">Artelo</a> added that the findings demonstrate the candidate’s potential as a candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing selective serotonin reuptake inhibitor therapies like Sertraline.ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to Cannabidiol or Epidiolex.Artelo CEO Gregory D Gorgas said that although strong antidepressant effects were noted with ART12.11 in prior studies, the company is “especially encouraged” by these new comparative findings.On Stocktwits, retail sentiment around Artelo, however, fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_12_27_08_PM_png_b2e63d4064.webp" alt="ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>ARTL stock is up by about 148% this year and by about 99% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-buying-hit-3-4-trillion-in-the-first-half-of-2025-yet-market-chatter-has-faded/chFtYldR5fx">Retail Buying Hit $3.4 Trillion In The First Half Of 2025, Yet Market Chatter Has Faded</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 

Equity

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 


Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs, leading to sensory, motor, or autonomic dysfunction.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107392/0/en/Artelo-Biosciences-Announces-Positive-First-in-Human-Data-for-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html">said</a> that all adverse events identified during the in-human trial were mild, transient, and self-resolving. Furthermore, the study demonstrated predictable pharmacokinetics for the drug.Pharmacokinetics is defined as the quantitative analysis of the processes of drug absorption, distribution, and elimination that determine the time course of drug action in response to an administered drug dose.The company said that complete dose-exposure profiles were explored, and tests confirmed dose-dependent, linear absorption across the evaluated range.Andrew Yates, Chief Scientific Officer at Artelo, said that the company is “particularly pleased” that the safety and pharmacokinetic profile generated from ART26.12’s non-clinical studies translated well to the human experience.According to Artelo, the chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.On Stocktwits, retail sentiment around ARTL jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_30_at_1_46_11_PM_png_54bfa7b48c.webp" alt="ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, flagged that the company will need cash to progress its pipeline, and hence, dilution is likely.<stembedurl>https://stocktwits.com/ElPutoToro/message/619463192</stembedurl>The company had cash and investments totaling only $0.7 million as of the end of the first quarter.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up by about 135% this year and by about 85% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q2-deliveries-expected-to-fall-below-consensus-jpmorgan-underscores-sizable-shortfall/chmZF6zRR7Q">Tesla Q2 Deliveries Expected To Fall Below Consensus, JPMorgan Underscores A ‘Sizable’ Shortfall</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.

The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.


Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Artelo Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $AMZN earnings on Thursday?

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ARTL News

ARTLArtelo Biosciences Inc